Clinical Trials
28 trialsNCT06131398 2026-05-28
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
Phase 1 Active not recruiting
NCT04389632 2026-05-11
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT05581004 2026-05-11
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT07218003 2026-05-04
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
NCT05187182 2026-04-27
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT05208762 2026-04-20
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT07227168 2026-03-05
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
Phase 1 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT02903914 2025-08-05
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT04660929 2024-12-18
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Unknown
NCT02635672 2024-11-15
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Completed
NCT03809624 2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1 Terminated
NCT05215574 2024-10-10
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Active not recruiting
NCT03621982 2024-06-13
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT04336098 2024-06-04
Study of SRF617 in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT04187872 2023-12-27
TORCH
University of Florida
Phase 1 Terminated
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT04460456 2022-06-30
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
Phase 1 Unknown
NCT02757391 2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02346955 2020-08-27
MK-6018-001
KitovPharma
Phase 1 Terminated
NCT03511222 2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT02563548 2020-02-07
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
Halozyme Therapeutics
Phase 1 Completed